Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Biomolecules · 09.10.2023 · 13 (10) · 1497
DOI: 10.3390/biom13101497 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 09.10.2023. Verfasst von Maryam Youssef und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada. Hauptthemen laut MEDLINE: Pandemics, COVID-19. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada (NSERC), Fonds de recherche—Nature et technologies Québec (FRQNT), Faculty of Engineering at McGill University.
Abstract (Originalsprache)
Recent advances and discoveries in the structure and role of mRNA as well as novel lipid-based delivery modalities have enabled the advancement of mRNA therapeutics into the clinical trial space. The manufacturing of these products is relatively simple and eliminates many of the challenges associated with cell culture production of viral delivery systems for gene and cell therapy applications, allowing rapid production of mRNA for personalized treatments, cancer therapies, protein replacement and gene editing. The success of mRNA vaccines during the COVID-19 pandemic highlighted the immense potential of this technology as a vaccination platform, but there are still particular challenges to establish mRNA as a widespread therapeutic tool. Immunostimulatory byproducts can pose a barrier for chronic treatments and different production scales may need to be considered for these applications. Moreover, long-term storage of mRNA products is notoriously difficult. This review provides a detailed overview of the manufacturing steps for mRNA therapeutics, including sequence design, DNA template preparation, mRNA production and formulation, while identifying the challenges remaining in the dose requirements, long-term storage and immunotolerance of the product.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada.
ORCID-Profile: Maryam Youssef, Cynthia Hitti, Julia Puppin Chaves Fulber, Amine A Kamen
Förderung
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Fonds de recherche—Nature et technologies Québec (FRQNT)
- Faculty of Engineering at McGill University
- Canada Research Chairs
Zitieren
APA
Youssef, M., Hitti, C., Puppin Chaves Fulber, J., & Kamen, A. A. (2023). Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules, 13(10), 1497. https://doi.org/10.3390/biom13101497
Vancouver
Youssef M, Hitti C, Puppin Chaves Fulber J, Kamen AA. Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules. 2023;13(10):1497. doi:10.3390/biom13101497
BibTeX
@article{Youssef2023,
author = {Youssef, Maryam and Hitti, Cynthia and Puppin Chaves Fulber, Julia and Kamen, Amine A},
title = {Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {10},
pages = {1497},
doi = {10.3390/biom13101497}
}
EUVIMED